Gilead Sciences, Inc.

Gilead Pharmasset LLC

The University of North Carolina at Chapel Hill

Zheng-Yu Yang

Jeromy J Cottell

James G Taylor

Sheila M Zipfel

John O Link

Elizabeth M Bacon

Darryl Kato

Elbert Chin

Teresa Alejandra Trejo Martin

Chinh Viet Tran

Hyung-Jung Pyun

Jeff A Zablocki

Choung U Kim

Barton W Phillips

Scott D Schroeder

Dustin S Siegel

Michael L Mitchell

Eda Y Canales

Tetsuya Kobayashi

Manoj C Desai

Winston C Tse

Gregory Notte

William A Lee

John C Rohloff

William John Watkins

Michael Graupe

Kevin S Currie

Scott A Mitchell

Chandrasekar Venkataramani

Kuo-Hsiung Lee

Scott E Lazerwith

Peter A Blomgren

Jianjun Xu

Seung H Lee

Juan A Guerrero

Zhongdong Zhao

Sundaramoorthi Swaminathan

Richard L Mackman

Matthew A Williams

Aesop Cho

Lianhong Xu

Jeffrey E Kropf

Peter H Nelson

Jennifer R Zhang

Sheng-Chu Kuo

James Ming Chen

Kuei-Ying Lin

Jay P Parrish

Michael O'Neil Hanrahan Clarke

Hongtao Liu

Hongyan Guo

Ashley Anne Katana

Chienhung Chou

Nathan E Wright

Gediminas J Brizgys

Evan S Krygowski

Stephen E Ammann

Nathan D Shapiro

Chao-I Hung

Marilyn Ndukwe

Adam James Schrier

Randall W Vivian

Michael Sangi

Rhiannon Thomas-Tran

Ruben Martinez

Kapil Kumar Karki

Gong-Xin He

Jianying Wang

Jiayao Li

Zhimin Du

Gary Paul Cook

Kyla Bjornson

Suzanne M Szewczyk

Marina Shatskikh

Haolun Jin

Aaron C Schmitt

Edward Doerffler

Jayaraman Chandrasekhar

Kirk L Stevens

Maria Fardis

Carina E Cannizzaro

Samuel E Metobo

Qi Liu

Ryan McFadden

Yi Xia

Jennifer R Lo

Julie Farand

Michael R Mish

Lijun Zhang

Xiaowu Chen

David W Lin

Evangelos Aktoudianakis

Kenneth F Bastow

Chien-Hung Chou

Murty N Arimilli

Terry Kellar

Jin-Ming Xiong

James D Trenkle

Christopher P Lee

Joseph H Saugier

The present disclosure provides GLP-1R agonists, and compositions, methods, and kits thereof. Such compounds are generally useful for treating a GLP-1R mediated disease or condition in a human.

GLP-1R modulating compounds

Provided herein are compounds and methods for the treatment or prevention of Zika virus infection. For example, a compound of the formula(I): Wherein the variable substituents are described herein.

Tetracyclic compounds and methods for the treatment of Zika virus infection

The invention provides a compound of Formula I: or a pharmaceutically acceptable salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of Formula I, processes for preparing compounds of Formula I, therapeutic methods for treating the proliferation of the HIV virus, treating AIDS or delaying the onset of AIDS symptoms in a mammal using compounds of Formula I.

HIV inhibitor compounds

The present disclosure relates generally to compounds that inhibit PRMT5. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through inhibiting PRMT5. The disclosure further relates to the use of the compounds for the treatment of a disease or condition associated with chromosome 9p21 deletion, MTAP null, or any other MTAP deficiency. The disclosure further relates to the use of the compounds for the treatment of cancers.

PRMT5 inhibitors and uses thereof

A compound of Formula (I): pharmaceutically acceptable salts thereof, deuterated analogs thereof, compositions thereof, and methods of treating disease using a compound thereof, wherein the variable substituents are disclosed herein.

Pyrrolo[1,2-b]pyridazine derivatives

The present disclosure provides GLP-1R agonists, and compositions, methods, and kits thereof. Such compounds are generally useful for treating a GLP-1R mediated disease or condition.

The invention provides a compound of Formula I:

A compound of Formula (I): pharmaceutically acceptable salts thereof, deuterated analogs thereof, compositions thereof, and methods of treating disease using a compound thereof are disclosed.

Thiadiazole IRAK4 inhibitors

Provided herein are compounds of Formula (I):

Pentacyclic derivatives as Zika virus inhibitors

Growing community of inventors

Palo Alto, CA, United States of America

Zheng-Yu Yang